Data, narratives and tools produced by the Kits' sector/GeneDxChart
Jump to navigation
Jump to search
Type | disease / drug tested | genes | patent holder and/or exclusive licensees | Companies | Number of US labs offering testing | license | key patents | other patents | product | typical testing cost | notes | report | links | References | ||||
Dx | Breast & Ovarian Cancer | BRCA1 | Myriad Genetics | Myriad Genetics | 1 | exclusive | 5753441, 6051379, | BRACAnalysis | $3120 [2] | [1], [2] | http://www.myriad.com/products/bracanalysis.php | [1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | ||||||
BRCA2 | [2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||||||||||||||||
Dx | colorectal cancer (HNPCC) | MLH1 | Oregon Health Sciences University + Dana Farber; Johns Hopkins | Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | ? | ? | 5922855, 5591826 (protein), 5693470 | ? | Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | [1], [2] | [3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | ||||||
MSH2 | ||||||||||||||||||
MSH6 | ||||||||||||||||||
Dx | colorectal cancer (FAP) | APC | ||||||||||||||||
MYH | ||||||||||||||||||
Dx | Alzheimer’s, late-onset (LOAD, AD2) | APOE | Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | 1 | exclusive | 5508167, 5716828, 6027896 | ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | $475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||||||
Alzheimer’s, early-onset (EOAD, AD3) | PSEN1 | Hospital for Sick Children, U Toronto -> Athena | Athena | 1 | exclusive | 6194153 | 5986054, 6531586, 6248555(dropped), | ADmark® PS-1 DNA Sequencing Test | $1675 ([2]B-15) | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | ||||||||
Alzheimer’s, early-onset (EOAD, AD4) | PSEN2 | Hospital for Sick Children -> Athena | Athena | 1 | exclusive | 5840540 | 6485911 | ADmark® PS-2 DNA Sequencing Test | $1500?* | * http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||||||
Alzheimer’s, early-onset (EOAD, AD1) | APP | ? | Athena | 2 | ? | ? | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | $1000?* | Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | ||||||||
Dx | Haemochromatosis | HFE | Bio-Rad | mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||||||||||||
Dx | Cystic Fibrosis | CFTR | University of Michigan, Hospital for Sick Children | 112 | non-exclusive | 5776677 | 5876974, 7118911, 6984487, 6730777, 5407796 | Johns Hopkins also has some key CFTR patents. | ||||||||||
Dx | Long-QT syndrome | PGxHealth; Bio-Reference Laboratories | [1], [2] | |||||||||||||||
Dx | Spinocerebellar Ataxia | Athena Diagnostics | exclusive | Cook-Deegan notes “penumbra effect” wrt Athena | [1], [2] | |||||||||||||
Dx | Tay-Sachs Disease | [1], [2] | ||||||||||||||||
Dx | Canavan Disease | [1], [2] | ||||||||||||||||
PGx | Coumadin (Warfarin) | CYP2C9 | Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | [3] | http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||||||||||||
PGx | Coumadin (Warfarin) | VKORC1 | [3] | |||||||||||||||
PGx | Sprycel (dasatinib) | BCR-ABL | [3] | http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11215 | ||||||||||||||